Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis

Journal of Rheumatology

Volumn 24, Issue 2, 1997, Pages 328-332

  Hasegawa, Minoru ^a   Fujimoto, Manabu ^b   Kikuchi, Kanako ^b   Takehara, Kazuhiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

enzyme linked immunosorbent assay; interleukin 10; interleukin 13; interleukin 4; systemic sclerosis

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-13; INTERLEUKIN-4; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

EID: 0031056613     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Roumm AD, Whiteside TL, Medsger TA Jr, Rodnan GP: Lymphocytes in the skin of patients with progressive systemic sclerosis. Arthritis Rheum 1984;27:645-53.
2. Paul WE: Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 1991;77:1859-70.
3. Howard M, O'Garra A, Ishida H, Malefyt RDW, de Vries J: Biological properties of interleukin 10. J Clin Immunol 1992;12:239-47.
4. Zurawski G, de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19-26.
5. Famularo G, Giacomelli R, Alesse E, et al: Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989;29:59-63.
6. Howard M, Farrar J, Hilfiker M, et al: Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med 1982;155:914-23.
7. Famularo G, Procopio A, Giacomelli R, et al: Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990;81:368-72.
8. Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-72.
9. Rousset F, Garcia E, Defrance T, et al: Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-3.
10. Llorente L, Zou W, Levy Y, et al: Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
11. Cush JJ, Splawski JB, Thomas R, et al: Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum 1995;1:96-104.
12. Minty A, Chalon P, Derocq JM, et al: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993;362:248-50.
13. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
14. LeRoy EC, Krieg T, Black C, et al: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
15. Steen VD, Powell DL, Medsger TA Jr: Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
16. Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-85.
17. Thornhill MH, Kyan-Aung U, Haskard DO: IL-4 increases human endothelial cell adhesiveness for T cells but not for neutrophils. J Immunol 1990;144:3060-5.
18. 1 mice. J Exp Med 1994;179:305-10.
19. Llorente L, Richaud-patin Y, Fior R, et al: In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. Arthritis Rheum 1994;11:1647-55.